103 related articles for article (PubMed ID: 3690549)
41. Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay.
Oppitz MM; Musch E; Malek M; Rüb HP; von Unruh GE; Loos U; Mühlenbruch B
Cancer Chemother Pharmacol; 1989; 23(4):208-12. PubMed ID: 2924378
[TBL] [Abstract][Full Text] [Related]
42. Prednisolone plasma levels after oral administration of Prednimustine. Comparison with levels obtained after administration of an equimolar dose of prednisolone.
Sayed A; Hove WV; Vermeulen A
Oncology; 1981; 38(6):351-5. PubMed ID: 7301281
[TBL] [Abstract][Full Text] [Related]
43. Phase II trial of 4-demethoxydaunorubicin in patients with advanced malignant melanoma.
Stanton G; Casper ES; Friedman B
Cancer Treat Rep; 1985; 69(7-8):915-6. PubMed ID: 3860298
[No Abstract] [Full Text] [Related]
44. Long-term toxicology effects of prednimustine in comparison with chlorambucil, prednisolone, and chlorambucil plus prednisolone in Sprague-Dawley rats.
Berger MR; Habs M; Schmähl D
Semin Oncol; 1986 Mar; 13(1 Suppl 1):8-13. PubMed ID: 3952521
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of high-dose megestrol acetate in patients with advanced malignant melanoma.
Creagan ET; Schutt AJ; Ahmann DL; Green SJ
Cancer Treat Rep; 1982 May; 66(5):1239-40. PubMed ID: 7083227
[No Abstract] [Full Text] [Related]
46. Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line.
Hartley-Asp B; Gunnarsson PO; Liljekvist J
Cancer Chemother Pharmacol; 1986; 16(2):85-90. PubMed ID: 3948307
[TBL] [Abstract][Full Text] [Related]
47. [Clinical experiences in tumor-oriented anti-cancer drugs].
Ohsawa N
Nihon Naika Gakkai Zasshi; 1988 Mar; 77(3):313-7. PubMed ID: 2841390
[No Abstract] [Full Text] [Related]
48. The clinical pharmacology of chlorambucil and prednimustine.
Newell DR; Calvert AH; Harrap KR; McElwain TJ
Br J Clin Pharmacol; 1983 Dec; 16(6):762-3. PubMed ID: 6661370
[No Abstract] [Full Text] [Related]
49. Evaluation of S12363, a novel vinca alkaloid drug in the treatment of advanced malignant melanoma. A phase II study.
Stanley AJ; Kaprielian R; Retsas S
Anticancer Res; 1993; 13(1):31-2. PubMed ID: 8476226
[TBL] [Abstract][Full Text] [Related]
50. Mitolactol chemotherapy for malignant melanoma: a phase II study.
Malden LT; Coates AS; Milton GW; McCarthy WH; Levi JA; Woods RL; Byrne MJ; Reynolds PM; Fox RM; Hedley DW
Cancer Treat Rep; 1984; 68(7-8):1045-6. PubMed ID: 6744338
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of vindesine infusion in visceral metastatic malignant melanoma.
Wagstaff J; Anderson HA; Shiu W; Thatcher N
Cancer Treat Rep; 1983 Sep; 67(9):839-40. PubMed ID: 6883362
[No Abstract] [Full Text] [Related]
52. Phase II study of vindesine in metastatic malignant melanoma.
Arseneau JC; Mellette SJ; Kuperminc M; Wolter J
Cancer Treat Rep; 1981; 65(3-4):355-6. PubMed ID: 7237458
[No Abstract] [Full Text] [Related]
53. Phase II study of tamoxifen in patients with metastatic malignant melanoma.
Telhaug R; Klepp O; Børmer O
Cancer Treat Rep; 1982 Jun; 66(6):1437. PubMed ID: 7083247
[No Abstract] [Full Text] [Related]
54. Phase II study of AMSA in patients with metastatic malignant melanoma.
Houghton AM; Camacho F; Wittes R; Young CW
Cancer Treat Rep; 1981; 65(1-2):170-1. PubMed ID: 6894401
[No Abstract] [Full Text] [Related]
55. Phase II study of mitomycin in disseminated malignant melanoma.
Creagan ET; Edmonson JH; Ahmann DL; Chang M
Cancer Treat Rep; 1985 Dec; 69(12):1451-2. PubMed ID: 4075321
[No Abstract] [Full Text] [Related]
56. Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma.
Berman E; Casper ES; Howard J; Wittes RE
Cancer Treat Rep; 1984 Apr; 68(4):679-80. PubMed ID: 6585272
[TBL] [Abstract][Full Text] [Related]
57. Comparison of the cytotoxic effect of prednimustine in cultured cells with high or low levels of metallothionein.
Endresen L
Acta Pharmacol Toxicol (Copenh); 1984 Jan; 54(1):49-57. PubMed ID: 6702467
[TBL] [Abstract][Full Text] [Related]
58. Phase II trial of esorubicin in patients with advanced melanoma.
Frustaci S; Gasparini G; Galligioni E; Tirelli U; Di Pietro N; Crivellari D; Lo Re G; Monfardini S
Cancer Treat Rep; 1987 Mar; 71(3):325-6. PubMed ID: 3815399
[No Abstract] [Full Text] [Related]
59. Phase II study of mitolactol in metastatic malignant melanoma.
Simmonds MA; Lipton A; Harvey HA; Ellison N; White DS
Cancer Treat Rep; 1985 Jan; 69(1):65-7. PubMed ID: 3967260
[TBL] [Abstract][Full Text] [Related]
60. On the clinical pharmacology of prednimustine.
Plym Forshell G; Gunnarsson PO; Liljekvist J
Br J Clin Pharmacol; 1983 Dec; 16(6):760-1. PubMed ID: 6661369
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
